Cover Image

New and emerging lipid-modifying drugs to lower LDL cholesterol

Cardiovascular disease (CVD) represents the leading cause of death worldwide. The role of low-density lipoprotein-cholesterol (LDL-C) in the pathophysiology of atherosclerosis and CVD has been well recognized. Statins are the standard of care for the management of hypercholesterolaemia, and their ef...

Full description

Saved in:

Bibliographic Details
Main Authors:	Constantine E Kosmas (Author), Dafni Pantou (Author), Andreas Sourlas (Author), Evangelia J Papakonstantinou (Author), Rogers Echavarria Uceta (Author), Eliscer Guzman (Author)
Format:	Book
Published:	BioExcel Publishing Ltd, 2021-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitus
by: Constantine E Kosmas, et al.
Published: (2018)

Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy
by: Constantine E Kosmas, et al.
Published: (2017)

Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia
by: Kosmas CE, et al.
Published: (2022)

Safety and Tolerability of PCSK9 Inhibitors: Current Insights
by: Kosmas CE, et al.
Published: (2020)

Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter?
by: Safi U. Khan, et al.
Published: (2020)

Primary genetic disorders affecting high density lipoprotein (HDL)
by: Constantine E Kosmas, et al.
Published: (2018)

Description of Discordance Between LDL Cholesterol, Non-HDL Cholesterol, and LDL Particle Number Among Patients of a Lipid Clinic
by: Joshua W Gaborcik, et al.
Published: (2017)

Targeting LDL Cholesterol With LNA
by: Arthur M Krieg
Published: (2012)

Erratum to "Cardiovascular Mortality after Intensive LDL-Cholesterol Lowering: Does Baseline LDL-Cholesterol Really Matter?" [American Journal of Preventive Cardiology 1C (2020) 100013]
by: Safi U. Khan, et al.
Published: (2021)

Therapeutic management of hyperlipoproteinemia (a)
by: Constantine E Kosmas, et al.
Published: (2019)

High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease
by: Constantine E Kosmas, et al.
Published: (2018)

LDL cholesterol values in a reference mature population
by: Karima Maricel Gondres Legró, et al.
Published: (2016)

A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations
by: K Gadkar, et al.
Published: (2014)

Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond
by: Maya Safarova, et al.
Published: (2024)

Electronegative LDL: A Circulating Modified LDL with a Role in Inflammation
by: Montserrat Estruch, et al.
Published: (2013)

Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register
by: Sofia Axia Karlsson, et al.
Published: (2018)

Dramatic LDL-Cholesterol elevation with Ketogenic Diet: A Case Series
by: David Harmon, et al.
Published: (2020)

Regulatory effect of Phikud Navakot extract on HMG-CoA reductase and LDL-R: potential and alternate agents for lowering blood cholesterol
by: Napatara Tirawanchai, et al.
Published: (2018)

Dramatic elevation of LDL cholesterol from ketogenic-dieting: A Case Series
by: Tyler Schmidt, et al.
Published: (2023)

Evaluation of statin use on LDL cholesterol levels in Turkey: A systematic review
by: Pınar Kızılırmak, et al.
Published: (2020)

Study of Lipid Profile in Obese Individuals and the Effect of Cholesterol Lowering Agents on Them
by: Surajit Kumar Mukhopadhyay
Published: (2012)

HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH) REQUIRES QUADRUPLE LIPID-LOWERING THERAPY TO ACHIEVE APPROPRIATELY LOW LDL-C
by: Viet Trung Le, DMSc, PA-C
Published: (2024)

Nonpharmacological cholesterol-lowering approach: Managing cholesterol naturally
by: Lubna Mahmood
Published: (2015)

Achievement of LDL-Cholesterol Goals in Patients Receiving LLT in Primary Care: TERESA-AP Study
by: Sergio Cinza-Sanjurjo, et al.
Published: (2024)

Cholesterol Lowering Therapies and Drugs
Published: (2016)

Lipid-lowering therapy and LDL-C control for primary prevention in persons with diabetes across 90 health systems in the United States
by: Emily Decicco, et al.
Published: (2023)

Hypochlorite-Modified LDL Induces Arrhythmia and Contractile Dysfunction in Cardiomyocytes
by: Chintan N. Koyani, et al.
Published: (2021)

Invasive Mechanical Ventilation and Death Was More Likely in Patients with Lower LDL Cholesterol Levels during COVID-19 Hospitalization: A Retrospective Propensity-Matched Cohort Study
by: Adhya Mehta, et al.
Published: (2023)

The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better
by: Omar Mhaimeed, et al.
Published: (2024)

Selected Soybean Varieties Regulate Hepatic LDL-Cholesterol Homeostasis Depending on Their Glycinin:β-Conglycinin Ratio
by: Miguel Rebollo-Hernanz, et al.
Published: (2022)

Lipid-lowering activity of Cow urine ark in guinea pigs fed with a high cholesterol diet
by: Hiren Manubhai Chawda, et al.
Published: (2014)

Oxidatively Modified LDL Suppresses Lymphangiogenesis via CD36 Signaling
by: Bhupesh Singla, et al.
Published: (2021)

Accuracy of 23 Equations for Estimating LDL Cholesterol in a Clinical Laboratory Database of 5,051,467 Patients
by: Christeen Samuel, et al.
Published: (2023)

Effects of extracted soy isoflavones alone on blood total and LDL cholesterol: Meta-analysis of randomized controlled trials
by: Kyoko Taku, et al.
Published: (2008)

Dyslipidemia in subclinical hypothyroidism requires assessment of small dense low density lipoprotein cholesterol (sdLDL-C)
by: Saric Maida Seferovic, et al.
Published: (2017)

Schistosoma haematobium infection is associated with lower serum cholesterol levels and improved lipid profile in overweight/obese individuals.
by: Jeannot F Zinsou, et al.
Published: (2020)

Alphataxin, an Orally Available Small Molecule, Decreases LDL Levels in Mice as a Surrogate for the LDL-Lowering Activity of Alpha-1 Antitrypsin in Humans
by: Cynthia L. Bristow, et al.
Published: (2021)

Carbon Nanodots Attenuate Lipid Peroxidation in the LDL Receptor Knockout Mouse Brain
by: Keith M. Erikson, et al.
Published: (2023)

The cholesterol-lowering effect of statins is modified by LILRB5 intolerance genotype: Results from a recruit-by-genotype clinical trial
by: Aleksi Tornio, et al.
Published: (2023)

Is the process of delivery of an individually tailored lifestyle intervention associated with improvements in LDL cholesterol and multiple lifestyle behaviours in people with Familial Hypercholesterolemia?
by: Broekhuizen Karen, et al.
Published: (2012)